Heritage Pharma Announces The Launch Of Prochlorperazine Injection

Jan 16, 2014, 11:22 ET from Heritage Pharmaceuticals Inc.

EATONTOWN, N.J., Jan. 16, 2014 /PRNewswire/ -- Heritage Pharmaceuticals Inc. ("Heritage") announced the immediate availability of Prochlorperazine Edisylate Injection in the 5mg/mL strength.  This product is the AP rated generic equivalent to the former brand Compazine and adds to Heritage's growing portfolio of generic injectable prescription products.  According to IMS data for the twelve-months ended December 2013, the U.S. market for Prochlorperazine Edisylate Injection approximated $5.5 million.

(Logo: http://photos.prnewswire.com/prnh/20140116/NY47775LOGO

About Prochlorperazine Edisylate Injection

Prochlorperazine Edisylate Injection is indicated for the treatment of severe nausea and vomiting.  The package insert, which is available at www.heritagepharma.com, contains detailed information about the indications, complete side effect profile and prescribing information.

About Heritage

Heritage Pharmaceuticals Inc. is a specialty pharmaceutical company engaged in the development, manufacturing, sales and marketing of generic and legacy branded pharmaceutical products for the U.S. prescription drug market.  Since inception, our customers have experienced the benefits of our continuous product expansion and global alliance network that has produced an impressive portfolio of over 150 products spanning multiple dosage forms. Heritage's products cover a number of therapeutic categories, including but not limited to: oncology, cardiovascular, metabolic disease, anti-infective and pain management.  Whether its oral solids or complex injectables, the Heritage portfolio is poised to continue to rapidly expand and deliver the Value Driven Medicine required to keep our customers competitive in the marketplace.   Let our formula of high quality and consistent supply work for you as we continue to provide affordable healthcare solutions to the U.S. consumer.


SOURCE Heritage Pharmaceuticals Inc.